STK33 and idiopathic pulmonary fibrosis: In addition, recently, selective DCLK1 [32] and STK33 inhibitors [33] have been reported, which may provide alternative therapeutic strategies for IPF by suppressing the proliferation of aberrant epithelial cells and inhibiting EMT, thus hindering the progression of fibrosis.